Mechanisms of psoriasis

Drug Discovery Today: Disease Mechanisms

Volumn 1, Issue 3, 2004, Pages 315-319

  Nestle, Frank O ^a   Conrad, Curdin ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CHEMOKINE; CYTOKINE; EFALIZUMAB; GAMMA INTERFERON; GROWTH FACTOR; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

B LYMPHOCYTE; CLINICAL TRIAL; DENDRITIC CELL; DISEASE MODEL; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; KERATINOCYTE; NONHUMAN; PSORIASIS; REVIEW; SKIN DEFECT; T LYMPHOCYTE;

EID: 23744498100     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2004.11.005     Document Type: Review

References (38)

1. Krueger, G. et al. (2001) The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 137, 280-284
2. Lew, W. et al. (2004) Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and 'Type 1' inflammatory gene expression. Trends Immunol. 25, 295-305
3. Nickoloff, B.J. and Nestle, F.O. (2004) Recent insights into the immuno-pathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113, 1664-1675
4. Gudjonsson, J.E. et al. (2004) Immunopathogenic mechanisms in psoriasis. Clin. Exp. Immunol. 135, 1-8
5. Griffiths, C.E. (2004) T-cell-targeted biologicals for psoriasis. Curr. Drug Targets Inflamm. Allergy 3, 157-161
6. Prinz, J.C. (2001) Psoriasis vulgaris - a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis Clin. Exp. Dermatol. 26, 326-332
7. Davidson, A. and Diamond, B. (2001) Autoimmune diseases. N. Engl. J. Med. 345, 340-350
8. Nestle, F.O. et al. (1994) Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J. Clin. Invest. 94, 202-209
9. Jones, D. A. et al. (2004) Identification of autoantigens in psoriatic plaques using expression cloning. J. Invest. Dermatol. 123, 93-100
10. Bowcock, A.M. and Barker, J.N. (2003) Genetics of psoriasis: the potential impact on new therapies. J. Am. Acad. Dermatol. 49, S51-S56
11. Chang, J.C. et al. (1994) CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. Proc. Natl. Acad. Sci. USA 91, 9282-9286
12. Ovigne, J.M. et al. (2001) Epidermal CD8+ T cells in chronic plaque psoriasis are Tc1 cells producing heterogeneous levels of interferon-gamma. Exp. Dermatol. 10, 168-174
13. Vissers, W.H. et al. (2004) Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br. J. Dermatol. 150, 852-859
14. Krueger, J.G. et al. (1995) Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J. Exp. Med. 182, 2057-2068
15. Lin, W.J. et al. (2001) Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions. J. Invest. Dermatol. 117, 1546-1553
16. Dustin, M.L. (2004) Stop and go traffic to tune T cell responses. Immunity 21, 305-314
17. Sterry, W. et al. (2004) Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br. J. Dermatol. 151 (Suppl. 69), 3-17
18. Ellis, C.N. and Krueger, G.G. (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345, 248-255
19. Abrams, J.R. et al. (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103, 1243-1252
20. Lebwohl, M. et al. (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349, 2004-2013
21. Feldmann, M. and Maini, R.N. (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163-196
22. Ghoreschi, K. et al. (2003) Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9, 40-46
23. Leonardi, C.L. et al. (2003) Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014-2022
24. Boyman, O. et al. (2004) Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-{alpha}. J. Exp. Med. 199, 731-736
25. Chaudhari, U. et al. (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357, 1842-1847
26. Gottlieb, A.B. et al. (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51, 534-542
27. Villadsen, L.S. et al. (2003) Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J. Clin. Invest. 112, 1571-1580
28. Wolk, K. et al. (2004) IL-22 increases the innate immunity of tissues. Immunity 21, 241-254
29. Lee, E. et al. (2004) Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199, 125-130
30. Nestle, F.O. and Conrad, C. (2004) The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J. Invest. Dermatol. (in press)
31. Homey, B. et al. (2002) CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat. Med. 8, 157-165
32. D'Ambrosio, D. et al. (2003) Special attractions for suppressor T cells. Trends Immunol. 24, 122-126
33. Homey, B. (2004) Chemokines and chemokine receptors as targets in the therapy of psoriasis. Curr. Drug Targets Inflamm. Allergy 3, 169-174
34. Nestle, F.O. and Nickoloff, B.J. (2004) From classical mouse models of psoriasis to a spontaneous xenograft model featuring use of AGR mice. Ernst Schering Res. Found Workshop 50, 203-212
35. Schon, M.P. (1999) Animal models of psoriasis - what can we learn from them? J. Invest. Dermatol. 112, 405-410
36. Boehncke, W.H. et al. (1999) The SCID-hu xenogeneic transplantation model allows screening of anti-psoriatic drugs. Arch. Dermatol. Res. 291, 104-106
37. Kupper, T.S. and Fuhlbrigge, R.C. (2004) Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 4, 211-222
38. Schon, M.P. et al. (2002) Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat. Med. 8, 366-372